Patient-Friendly Explanation
Somatostatin analogues are medicines given by injection (octreotide and lanreotide) that quieten down several hormones made by the gut and the pituitary gland. They can reduce appetite and blunt sharp hormone surges, so they are used in a few rare hormone-related weight problems and in low blood sugar attacks after weight-loss surgery.
Clinical Definition
These agents are synthetic somatostatin analogues acting mainly on SSTR2 and SSTR5, suppressing growth hormone, glucagon, insulin and gut peptide secretion. They are established therapy for acromegaly and neuroendocrine tumours and are used for post-bariatric hypoglycaemia. Weight effects vary by indication: they can reduce weight in hypothalamic obesity and hyperinsulinaemic states, but commonly cause steatorrhoea, cholelithiasis, flatulence and reduced fat-soluble vitamin absorption, and can blunt postprandial glucose excursions.
Why It Matters
Somatostatin analogues are relevant to weight management mainly in post-bariatric hypoglycaemia and rare hypothalamic obesity, where they can be genuinely useful. Patients on long-term therapy need gallbladder surveillance and monitoring of vitamins A, D, E, K and B12.